PPAR Research

PPAR Research / 2007 / Article

Review Article | Open Access

Volume 2007 |Article ID 030578 | https://doi.org/10.1155/2007/30578

Adnan Erol, "Muscle-Specific PPARβ/δ Agonism May Provide Synergistic Benefits with Life Style Modifications", PPAR Research, vol. 2007, Article ID 030578, 7 pages, 2007. https://doi.org/10.1155/2007/30578

Muscle-Specific PPARβ/δ Agonism May Provide Synergistic Benefits with Life Style Modifications

Academic Editor: Jihan Youssef
Received02 Jul 2007
Revised08 Aug 2007
Accepted13 Nov 2007
Published12 Dec 2007

Abstract

Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) has emerged as a powerful metabolic regulator in diverse tissues including fat, skeletal muscle, and the heart. It is now established that activation of PPARβ/δ promotes fatty acid oxidation in several tissues, such as skeletal muscle and adipose tissue. In muscle, PPARβ/δ appears to act as a central regulator of fatty acid catabolism. PPARβ/δ contents are increased in muscle during physiological situations such as physical exercise or long-term fasting, characterized by increased fatty acid oxidation. Targeted expression of an activated form of PPARβ/δ in skeletal muscle induces a switch to form increased numbers of type I muscle fibers resembling the fiber type transition by endurance training. Activation of PPARβ/δ also enhances mitochondrial capacity and fat oxidation in the skeletal muscle that resembles the effect of regular exercise. Therefore, it is hypothesized that muscle-specific PPARβ/δ agonists could be a key strategy to support the poor cardiorespiratory fitness associated with metabolic disorders.

References

  1. C. Gaudel and P. A. Grimaldi, “Metabolic functions of peroxisome proliferator-activated receptor β/δ in skeletal muscle,” PPAR Research, vol. 2007, Article ID 86394, 6 pages, 2007. View at: Publisher Site | Google Scholar
  2. Y.-X. Wang, C.-L. Zhang, and R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPARδ,” PLoS Biology, vol. 2, no. 10, pp. 1532–1539, 2004. View at: Publisher Site | Google Scholar
  3. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at: Publisher Site | Google Scholar
  4. C. K. Roberts and R. J. Barnard, “Effects of exercise and diet on chronic disease,” Journal of Applied Physiology, vol. 98, no. 1, pp. 3–30, 2005. View at: Publisher Site | Google Scholar
  5. F. W. Booth and R. A. Shanely, “The biochemical basis of the health effects of exercise: an integrative view,” in Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 199–203, Columbia, Mo, USA, May 2004. View at: Publisher Site | Google Scholar
  6. T. R. Koves, P. Li, and J. An et al., “Peroxisome proliferator-activated receptor-γ co-activator 1α-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33588–33598, 2005. View at: Publisher Site | Google Scholar
  7. A. P. Russell, J. Feilchenfeldt, and S. Schreiber et al., “Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-γ coactivator-1 and peroxisome proliferator-activated receptor-α in skeletal muscle,” Diabetes, vol. 52, no. 12, pp. 2874–2881, 2003. View at: Publisher Site | Google Scholar
  8. S. Trappe, M. Harber, and A. Creer et al., “Single muscle fiber adaptations with marathon training,” Journal of Applied Physiology, vol. 101, no. 3, pp. 721–727, 2006. View at: Publisher Site | Google Scholar
  9. E. Volpi, R. Nazemi, and S. Fujita, “Muscle tissue changes with aging,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 7, no. 4, pp. 405–410, 2004. View at: Publisher Site | Google Scholar
  10. D. Freyssenet, “Energy sensing and regulation of gene expression in skeletal muscle,” Journal of Applied Physiology, vol. 102, no. 2, pp. 529–540, 2007. View at: Publisher Site | Google Scholar
  11. A. Leal-Cerro, A. Gippini, and M. J. Amaya et al., “Mechanisms underlying the neuroendocrine response to physical exercise,” Journal of Endocrinological Investigation, vol. 26, no. 9, pp. 879–885, 2003. View at: Google Scholar
  12. J. Mercier, A. Perez-Martin, X. Bigard, and R. Ventura, “Muscle plasticity and metabolism: effects of exercise and chronic diseases,” Molecular Aspects of Medicine, vol. 20, no. 6, pp. 319–373, 1999. View at: Publisher Site | Google Scholar
  13. A. G. Smith and G. E. O. Muscat, “Skeletal muscle and nuclear hormone receptors: Implications for cardiovascular and metabolic disease,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 10, pp. 2047–2063, 2005. View at: Publisher Site | Google Scholar
  14. D. Pette, H. Peuker, and R. S. Staron, “The impact of biochemical methods for single muscle fibre analysis,” Acta Physiologica Scandinavica, vol. 166, no. 4, pp. 261–277, 1999. View at: Publisher Site | Google Scholar
  15. J. He, S. Watkins, and D. E. Kelley, “Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity,” Diabetes, vol. 50, no. 4, pp. 817–823, 2001. View at: Publisher Site | Google Scholar
  16. J. Norrbom, C. J. Sundberg, H. Ameln, W. E. Kraus, E. Jansson, and T. Gustafsson, “PGC-1α mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle,” Journal of Applied Physiology, vol. 96, no. 1, pp. 189–194, 2004. View at: Publisher Site | Google Scholar
  17. K. Baar, A. R. Wende, and T. E. Jones et al., “Adaptations of skeletal muscle to exercise: Rapid increase in the transcriptional coactivator PGC-1,” FASEB Journal, vol. 16, no. 14, pp. 1879–1886, 2002. View at: Publisher Site | Google Scholar
  18. S.-H. Koo, H. Satoh, and S. Herzig et al., “PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3,” Nature Medicine, vol. 10, no. 5, pp. 530–534, 2004. View at: Publisher Site | Google Scholar
  19. H. Liang and W. F. Ward, “PGC-1α: a key regulator of energy metabolism,” Advances in Physiology Education, vol. 30, no. 4, pp. 145–151, 2006. View at: Publisher Site | Google Scholar
  20. E. Hondares, I. Pineda-Torra, R. Iglesias, B. Staels, F. Villarroya, and M. Giralt, “PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle,” Biochemical and Biophysical Research Communications, vol. 354, no. 4, pp. 1021–1027, 2007. View at: Publisher Site | Google Scholar
  21. S. Luquet, J. Lopez-Soriano, and D. Holst et al., “Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability,” FASEB Journal, vol. 17, no. 15, pp. 2299–2301, 2003. View at: Publisher Site | Google Scholar
  22. P. Garcia-Roves, J. M. Huss, and D.-H. Han et al., “Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 25, pp. 10709–10713, 2007. View at: Publisher Site | Google Scholar
  23. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at: Publisher Site | Google Scholar
  24. O. Barbier, I. P. Torra, and Y. Duguay et al., “Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 717–726, 2002. View at: Publisher Site | Google Scholar
  25. S. Luquet, J. Lopez-Soriano, and D. Holst et al., “Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome,” Biochimie, vol. 86, no. 11, pp. 833–837, 2004. View at: Publisher Site | Google Scholar
  26. D. M. Muoio, D. B. MacLean, and D. B. Lang et al., “Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPARδ,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 26089–26097, 2002. View at: Publisher Site | Google Scholar
  27. U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E.O. Muscat, “The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells,” Molecular Endocrinology, vol. 17, no. 12, pp. 2477–2493, 2003. View at: Publisher Site | Google Scholar
  28. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at: Publisher Site | Google Scholar
  29. M. Schuler, F. Ali, and C. Chambon et al., “PGC1α expression is controlled in skeletal muscles by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes,” Cell Metabolism, vol. 4, no. 5, pp. 407–414, 2006. View at: Publisher Site | Google Scholar
  30. Y.-X. Wang, C.-H. Lee, S. Tiep, R. T. Yu, J. Ham, H. Kang, and R. M. Evans, “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at: Publisher Site | Google Scholar
  31. E. Barton and C. Morris, “Mechanisms and strategies to counter muscle atrophy,” Journals of Gerontology—Series A Biological Sciences and Medical Sciences, vol. 58, no. 10, pp. 923–926, 2003. View at: Google Scholar
  32. J. Lexell and D. Downham, “what is the effect of aging on type 2 muscle fiber?,” Journals of Neurol Science, vol. 107, no. 2, pp. 250–251, 1992. View at: Google Scholar
  33. M. R. Deschenes, “Effects of aging on muscle fiber type and size,” Sports Medicine, vol. 34, no. 12, pp. 809–824, 2004. View at: Google Scholar
  34. K. E. Conley, S. A. Jubrias, C. E. Amara, and D. J. Marcinek, “Mitochondrial dysfunction: impact on exercise performance and cellular aging,” Exercise and Sport Sciences Reviews, vol. 35, no. 2, pp. 43–49, 2007. View at: Publisher Site | Google Scholar
  35. Z. Arany, N. Lebrasseur, and C. Morris et al., “The transcriptional coactivator PGC-1β drives the formation of oxidative type IIX fibers in skeletal muscle,” Cell Metabolism, vol. 5, no. 1, pp. 35–46, 2007. View at: Publisher Site | Google Scholar
  36. C. Ling, P. Poulsen, and E. Carlsson et al., “Multiple environmental and genetic factors influence skeletal muscle PGC-1α and PGC-1β gene expression in twins,” Journal of Clinical Investigation, vol. 114, no. 10, pp. 1518–1526, 2004. View at: Publisher Site | Google Scholar
  37. Y. Kamei, H. Ohizumi, and Y. Fujitani et al., “PPARγ coactivator 1β/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12378–12383, 2003. View at: Google Scholar
  38. A. Oberbach, Y. Bossenz, and S. Lehmann et al., “Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 4, pp. 895–900, 2006. View at: Google Scholar
  39. G. E. O. Muscat and U. Dressel, “Cardiovascular disease and PPARδ: targeting the risk factors,” Current Opinion in Investigational Drugs, vol. 6, no. 9, pp. 887–894, 2005. View at: Google Scholar
  40. L. Cheng, G. Ding, and Q. Qin et al., “Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy,” Nature Medicine, vol. 10, no. 11, pp. 1245–1250, 2004. View at: Publisher Site | Google Scholar
  41. A. Planavila, R. Rodríguez-Calvo, M. Jové, L. Michalik, W. Wahli, J. C. Laguna, and M. Vázquez-Carrera, “Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005. View at: Publisher Site | Google Scholar
  42. T. Takahashi, T. Tanaka, and J. Sakai, “New therapeutic target for metabolic syndrome: PPARδ,” Endocrine Journal, vol. 54, no. 3, pp. 347–357, 2007. View at: Publisher Site | Google Scholar
  43. T. Tanaka, S. Yamamoto, and H. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003. View at: Google Scholar
  44. K. C. Choi, S. Y. Lee, and H. J. Yoo et al., “Effect of PPAR-δ agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 357, no. 1, pp. 62–67, 2007. View at: Publisher Site | Google Scholar
  45. C. Fürnsinn, T. M. Willson, and B. Brunmair, “Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport,” Diabetologia, vol. 50, no. 1, pp. 8–17, 2007. View at: Publisher Site | Google Scholar
  46. U. Seedorf and J. Aberle, “Emerging roles of PPARδ in metabolism,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 9, pp. 1125–1131, 2007. View at: Publisher Site | Google Scholar
  47. Y. Barak, D. Liao, and W. He et al., “Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002. View at: Publisher Site | Google Scholar
  48. M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters, “The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR),” Toxicological Sciences, vol. 90, no. 2, pp. 269–295, 2006. View at: Publisher Site | Google Scholar
  49. T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999. View at: Publisher Site | Google Scholar
  50. B. H. Park, B. Vogelstein, and K. W. Kinzler, “Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2598–2603, 2001. View at: Publisher Site | Google Scholar
  51. F. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gonzalez, and J. M. Peters, “Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis,” Nature Medicine, vol. 10, no. 5, pp. 481–483, 2004. View at: Google Scholar
  52. H. E. Marin, M. A. Peraza, and A. N. Billin et al., “Activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis,” Cancer Research, vol. 66, no. 8, pp. 4394–4401, 2006. View at: Publisher Site | Google Scholar
  53. R. L. Stephen, M. C. U. Gustafsson, and M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004. View at: Google Scholar
  54. L. Xu, C. Han, and T. Wu, “A novel positive feedback loop between peroxisome proliferator-activated receptor-δ and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 33982–33996, 2006. View at: Publisher Site | Google Scholar
  55. A. Erol, “Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress,” BioEssays, vol. 29, no. 8, pp. 811–818, 2007. View at: Publisher Site | Google Scholar

Copyright © 2007 Adnan Erol. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views93
Downloads423
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.